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Abstract
Objectives—To determine the prevalence of HPV and cervical neoplasia among HIV-infected
women in southwestern China.
Methods—Cervical cytology, HPV detection by Hybrid Capture-2™ assay, and diagnostic
colposcopy were followed by cervical biopsy if indicated. Logistic regression analysis was used to
analyze associations between HPV co-infection and cervical intraepithelial neoplasia (CIN), and
HIV-related clinical and laboratory parameters.
Results—Colposcopic-histopathologically proven CIN2+ lesions were present in 7/83 (8.4%)
HIV-infected women. Nearly half (41/83, 43%) were co-infected with carcinogenic HPV
genotypes. HPV co-infection was higher in women with colposcopic-histopathologically proven
CIN2+ lesions than women with <CIN1 after adjusting for age (OR: 8.3, 95% CI: 0.9, 73.4).
Women with CD4+ cell counts less than 350 cells/μL had higher CIN2+ prevalence after adjusting
for current ART status and age (adjusted OR: 6.3, 95% CI: 1.1, 36.5).
Conclusions—HIV/AIDS care and treatment programs should integrate effective cervical
cancer prevention services to mitigate the risk of invasive cervical cancer among HIV-infected
women in China.
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Introduction
Women infected with the human immunodeficiency virus (HIV) have a higher risk of
incidence and persistence of human papillomavirus (HPV)-associated cervical intraepithelial
neoplasia (CIN) and cervical cancer than women without HIV (Palefsky and Holly, 2003;
Strickler et al., 2005). The HIV/acquired immunodeficiency syndrome (AIDS) epidemic
first began in China among injection drug users (IDUs) in the Dehong Prefecture of Yunnan
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use and needle sharing were spurred by Dehong’s proximity to the “Golden Triangle” of
drug trafficking where Myanmar, Thailand, and Laos converge (Zhang et al., 2006; Jia et al.,
2008). It has been estimated that the HIV-1 prevalence rate reached over 80% among some
groups of IDUs in Yunnan, making it the most severely affected Chinese province (Lu et al.,
2004; Zhang et al., 2004). More than half (54.4%) of the approximately 15,000 IDUs in
Dehong prefecture are infected with HIV (Jia et al., 2008). The problems in Yunnan are
worrisome for the rest of China, as the country is estimated to have the world’s largest
population of IDUs (approximately 2.4 million), and 6.7–13.4% of these drug users are
currently living with HIV (Joint United Nations Programme on HIV/AIDS & World Health
Organization, 2010).
Despite the known increased risk for cervical cancer among this population, the burden of
HPV and cervical neoplasia among HIV-infected women in China has not been reported.
The advent of antiretroviral therapy (ART) against HIV and its increasing availability
worldwide has lengthened the life expectancy of HIV-infected women (Franceschi and
Jaffe, 2007). Yet in the absence of appropriate prevention services, the lengthened life span
makes HIV-infected women vulnerable to persistence of HPV infection and its development
to invasive cervical cancer (Franceschi and Jaffe, 2007). Cervical cytology, with its low to
moderate sensitivity, may underestimate the true prevalence of cervical cancer precursors in
HIV-infected women (Nanda et al., 2000; Sahasrabuddhe et al., 2011). Studies which use
diagnostic colpolscopy and, if indicated, histopathology, as well as HPV DNA testing, are
needed to investigate the true prevalence of CIN in this high-risk cohort of women to better
quantify risk, and our knowledge of HIV-HPV co-infection. We undertook a descriptive
epidemiology study in Mangshi, Dehong Prefecture, China to determine the prevalence and
predictors of HPV infection and colposcopic-histopathologically confirmed CIN among
HIV-infected women.
Materials and Methods
Study Setting and Participants
The Women and Children’s Hospital of Luxi County in Mangshi, Dehong Prefecture, was
chosen as the site of this study. Participants were recruited through outreach efforts by
hospital personnel familiar to the local HIV-infected population. Eligibility criteria included
having documented serologic evidence of HIV infection, no evidence of pregnancy, absence
of debilitating illness that might have precluded a pelvic examination, no prior history of
screening or treatment for cervical neoplasia, and no prior hysterectomy. Participants were
recruited regardless of their CD4+ counts or current ART status. The study was approved by
the institutional review boards of Vanderbilt University and the Cancer Institute and
Hospital, Chinese Academy of Medical Sciences (CICAMS).
Study Procedures
After detailed explanation of study procedures, a chance for participants to ask questions,
and obtaining written informed consent, trained nurses administered a questionnaire to
collect sociodemographic information, sexual and reproductive history, and medical history
relevant to HIV/AIDS and cervical cancer. A blood sample was obtained for CD4+ T-cell
count estimation, and tested at the Center for Disease Control and Prevention, Dehong,
China. All women underwent a pelvic examination by a trained gynecologist. Specimens
were taken from the ectocervix and endocervix for Pap smears (cytology) using a plastic
Ayers spatula and a cytobrush, respectively. Cervical samples were also collected from the
endocervix to test for the presence of high-risk HPV DNA using the Digene Hybrid Capture
2™ (HC2) assay (Qiagen, Inc., Gaithersburg, MD, USA) in a certified laboratory as per
manufacturer’s instructions. (Terry et al., 2001) On all participants, visualization of the
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cervix was performed with acetic acid and Lugol’s iodine followed by colposcopy. Cervical
punch biopsies were advised and performed on consenting participants with clinical
evidence of cervical abnormalities and a trained pathologist analyzed the histopathology
samples (Dr Pu Ping, Pathology Department, Kunming Medical University, China). The
final diagnosis for each woman was based on either the histopathology results whenever
available, or on the initial colposcopy impression if no biopsy was performed or the
histopathology results were inconclusive. Results were reported as per the Bethesda CIN
staging system by increasing disease severity: normal/no neoplastic abnormalities, CIN1,
CIN2, CIN3, or invasive cervical cancer (ICC) (Richart, 1973).
Statistical Analysis
The statistical analysis was conducted using STATA 11.1 (StataCorp LP, College Station,
TX, USA). Women HC2 test positive or with CD4+ counts lower than 350 cells/μL were
stratified by cytology and colposcopic-histopathological diagnosis; data were analyzed with
bivariate logistic regression to identify associations between these variables. Crude and
adjusted odds ratios and confidence intervals were also calculated to identify
sociodemographic and clinical characteristics predicting diagnoses of CIN and high-risk
HPV DNA positivity (Harrell et al., 1985). Sensitivity and specificity estimates were
calculated for the HC2 HPV DNA and Pap smear tests.
Results
Sociodemographic Information
In April 2009, 96 HIV-infected women were recruited for this study. One patient who
consented did not eventually participate in the clinical protocol, and thus data from 95
women were included in subsequent analyses. The mean age of participants was 33.5 years,
with a range from 19–68 years. The median CD4+ count was 441 cells/μL and slightly more
than half (55/95, 57.9%) of the participants were concurrently taking anti-retroviral therapy
for their HIV infection (Table 1).
Colposcopy and Histopathology
Colposcopy was performed on all but three participants, one of which experienced heavy
cervical bleeding post-sample collection and two refused consent for the colposcopy portion
of the exam. Of the remaining 92 women, 12 had unsatisfactory colposcopy examinations
but refused endocervical curettage (ECC) at that time. Three of these women later tested
positive for both cervical intraepithelial lesions by Pap smear and HPV high-risk DNA by
HC2 test and were called back to the clinic for ECC and cervical biopsies. As a result, a total
of 83 women were given a final colposcopic-histopathological diagnosis from this study.
Fifty-five women (66.3%) had no evidence of CIN on colposcopy, 16 women (19.3%)
showed evidence of CIN1 and 9 women (10.8%) showed evidence of CIN2+ lesions.
The final composite colposcopic-histopathological diagnoses revealed no evidence of CIN
in 67 out of 83 women (80.7%). CIN1 was reported in 9 women (9.5%), CIN2 in 5 women
(5.3%), and CIN3 in 2 women (2.1%). Invasive cervical cancer was not reported in any
women (Table 1). Thus, of women with a final diagnosis, 16/83 (19.3%) had evidence of
CIN1+ lesions and 7/83 (8.4%) had evidence of CIN2+ lesions.
Cytology and HPV DNA Testing
Specimens for cytology and high-risk HPV DNA testing were collected from every
participant before colposcopy. Seventy-five women (79%) tested negative for pre-cancerous
lesions, seven showed atypical squamous cells of undetermined significance (ASC-US), 12
showed low-grade intraepithelial lesions (LSIL) and one showed high-grade intraepithelial
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lesions (HSIL). Of women who tested negative on cytology, 48 women (75%) were negative
by colposcopy as well, but 13 women (20.3%) had evidence of CIN1 on colposcopy, and
three women (4.7%) had CIN2+. Of women who tested ASC-US/LSIL on cytology, six
(40%) had CIN2+. Of women who tested negative on the HC2 DNA test, six (14.0%) had
evidence of CIN1 and two (4.7%) had evidence of CIN2+ (Table 2). Forty-one HIV-infected
women (43.2%) tested positive for high-risk HPV DNA per the HC2 test. Using the
colposcopic-histopathological diagnosis as the reference standard, the sensitivity of the HC2
test for CIN2+ in this study was 85.7% (95% confidence interval (CI): 42.0–99.2) while the
specificity was 55.3% (95%CI: 43.5–66.5). The sensitivity of cytology for a comparable
level of cervical lesion (HSIL) detection was lower at 6.3% (95% CI: 0.0–47.1), but the
specificity was higher at 98.1% (95% CI: 91.1–99.8) (Figure 1). Compared to women with
normal cytology results, women with ASC-US, LSIL, and HSIL cytology had progressively
higher rates of HPV infection (Table 3).
Predictors of Increasing Severity of CIN and Positivity for High-Risk HPV DNA
In analysis adjusted only for age, participants whose CD4+ counts were lower than 350
cells/μL had greater odds of CIN2+ as opposed to ≤ CIN1 (OR: 6.8, 95% CI: 1.2, 38.3)
(Table 4). Although the odds decreased slightly when current ART status was added as a
variable, the relationship maintained significance (OR: 6.3, 95% CI: 1.1, 36.5). Women with
both CIN1+ and CIN2+ had higher HPV DNA prevalence than <CIN1 and <CIN2
respectively, although the difference reached the statistically significant level only in CIN1+
women due to the small sample size. Women with two or more lifetime sexual partners were
more likely to be high-risk HPV DNA positive than women with less than two sexual
partners, a difference which approached statistical significance.
Discussion
Our study is the first report to date on prevalence and factors associated with HPV and
cervical precancerous lesions among HIV-infected women in China. This study showed that
HIV-infected women have a high burden of high-risk HPV DNA and CIN disease, and
increasing risk with further immunosuppression as measured by lower CD4 counts.
Contemporaneous CIN1+ prevalence rates from the general population in China have ranged
from 7.3 to 10% (Belinson et al., 2003; Pan et al., 2003; Ting et al., 2010) as compared to
over 19% women in this study with evidence of CIN1+. A recent review of cervical cancer
and HPV burden in China estimated the prevalence of high-risk HPV DNA to be 17.2% (Shi
et al., 2011), a figure much lower than the 43.1% found in our population of HIV-infected
women. While not as high as the 70 to 80% or higher prevalence estimates from HIV-
infected women in sub-Saharan African countries with generalized HIV epidemics (e.g.,
Zambia (Sahasrabuddhe et al., 2007), South Africa (Denny et al., 2008) and Kenya
(Luchters et al., 2010)), these rates are similar to those reported from studies reporting HPV
DNA prevalence among HIV-infected women from countries with low-level or concentrated
HIV epidemics like India (Sahasrabuddhe et al., 2010), Brazil (de Andrade et al., 2011), and
elsewhere (Tornesello et al., 2008; Videla et al., 2009).
The use of combined histopathology following colposcopy for women with clinical evidence
of CIN as the diagnostic standard in this study avoided unnecessary invasive procedures
while increasing the accuracy of diagnosis over that of cytology, or even that of colposcopy
alone (Dexeus et al., 2002; Kosinski and Barnhart, 2003). It also enabled us to compare
colposcopy results with cytological results in the same cohort of HIV-infected women.
Twenty-five percent of women in our study who tested negative by cytology actually had
some form of colposcopic evidence of CIN, and 40% of women with ASC-US or LSIL by
cytology had CIN2+ as determined by colposcopy (Table 2). These data also suggest that
cytology testing for cervical lesions is even less accurate in HIV-infected women than for
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the general population, as confirmed in other studies (Akinwuntan et al., 2008;
Sahasrabuddhe et al., 2011). On the other hand, while the sensitivity of HPV testing was
higher than cytology, it came at a significant loss of specificity (Figure 1). Given the high
prevalence of HPV DNA among HIV-infected women, and the possibility of significant
numbers testing positive using HPV-based screening, further research is needed to improve
specificity (and reduce false positive referrals) by the use of molecular biomarkers (such as
p16ink4a or E6/E7 mRNA) in conjunction with HPV testing.
Our study demonstrates that the presence of carcinogenic HPV DNA is an independent
predictor of CIN and also shows that HIV-infected women with low CD4+ counts are at
higher risk for pre-cancerous cervical lesions than women with higher CD4+ counts. These
risk factors and the high prevalence of CIN in this population compared to the general
population demand targeted screening and treatment for HIV-infected women to prevent
high mortality from cervical cancer. China is investing new resources for nationwide
expansion of the cervical cancer screening program to tackle the historically inadequate
population coverage common to most developing countries. (Gakidou et al., 2008) Efforts
are focusing on the development of low-cost, rapid HPV-based diagnostics, which should be
effectively integrated with HIV/AIDS care and treatment programs (Mwanahamuntu et al.,
2008; Qiao et al., 2008).
Our study had several limitations. We were only able to obtain CD4+ counts at the time of
enrollment (as opposed to nadir CD4+ counts), which could incompletely reflect immune
status. Also, colposcopic and histopathologic interpretations are subjective and are rater-
dependent (Massad et al., 2001), raising the possibility of systematic misclassification of
cervical lesions. Importantly, the cross-sectional study design precludes any evidence of
causality and the small sample size does not allow adequate power for many statistical
comparisons. We are currently conducting a prospective study in a larger cohort in the same
area of Yunnan Province, China to better study the natural history of HPV co-infection and
cervical neoplasia in HIV-infected women and the effect of ART in this high-risk
population.
Our study is the first to demonstrate that HIV-infected women in southwest China have a
high prevalence of carcinogenic HPV and precancerous lesions relative to the general
population. In the context of constantly improving ART access and life expectancies among
HIV-infected people, the importance of instituting early and effective detection and
treatment services to protect this high-risk population from developing invasive cervical
cancer cannot be understated.
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Table 1
Sociodemographic and Laboratory Results of the Study Participants
Information All participants (N=95)
Mean age, years (range) 33.5 (19–68)
Nationality, N (%)
  Han 43 (45.3)
  Dai 32 (33.7)
  Jing Bo 11 (11.6)
  Othera 9 (9.5)
Median CD4+ counts, cells/μL (range) 441 (89–6789)
ART treatment, N (%) 55 (57.9)
Mean duration of ART use, months (range)b 23.6 (3–59)
 Mean number of sexual partners (range) 1.91 (1–30)
 Number of smokers, N (%) 9 (9.5)
 Median parity (range) 2 (0–6)
 HPV DNA positivityc, N (%) 41 (43.1)
 Women with normal cytology 25 (33.3)
Cytology, N (%)
  Negative 75 (79.0)
  ASC-US 7 (7.4)
  LSIL 12 (12.6)
  HSIL 1 (1.1)
Coloposcopic-histopathological diagnosisd, N (%)
  No evidence of CIN 67 (70.5)
  CIN1 9 (9.5)
  CIN2 5 (5.3)
  CIN3 2 (2.1)
  Unsatisfactory/Missinge 12 (12.6)
a
Other nationalities: De An (5 women), Hui (1), Wei Wu Er (1), Bu Yi (1), and Ar Chan (1);
b
Mean duration of ART use for those taking ART;
c
HPV DNA Positive if Hybrid Capture 2™ result ≥1.00 relative light units;
d
Colposcopic-Histopathological diagnosis: Biopsy results if available or colposcopy results if no biopsy;
e
Unsatisfactory/missing colposcopic-histopathological diagnoses: 9 unsatisfactory and 3 missing; ART, Anti-retroviral HIV therapy; CIN, Cervical
intraepithelial neoplasia; ASC-US, Aytpical squamous cells of undetermined significance; LSIL, Low-grade squamous intraepithelial lesion; HSIL:
High-grade squamous intraepithelial lesion
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Table 2
Comparison of Colposcopy with Cytology and HPV DNA Results among HIV-infected Women
Colposcopy result N %
Cytology
 Negative Negative 48 75
CIN1 13 20.3
CIN 2+ 3 4.7
 ASC-US/LSIL Negative 6 40
CIN1 3 20
CIN 2+ 6 40
 HSIL Negative 1 100
CIN1 0 0
CIN 2+ 0 0
HPV Testing
 Negative Negative 35 81.4
CIN1 6 14
CIN 2+ 2 4.7
 Positivea Negative 20 66.7
CIN1 10 33.3
CIN 2+ 0 0
a
HPV positive: HC2 ≥ 1.00 relative light units (RLU); CIN, Cervical intraepithelial neoplasia; ASC-US, Aytpical squamous cells of undetermined
significance; LSIL, Low-grade squamous intraepithelial lesion; HSIL, High-grade squamous intraepithelial lesion
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